Stock Track | Vir Biotechnology (VIR) Soars 5.03% on Bullish Analyst Ratings

Stock Track
2025/11/12

Shares of Vir Biotechnology, Inc. (VIR) are surging in intraday trading, with the stock price soaring 5.03%. This significant uptick comes on the heels of bullish analyst ratings from two major financial institutions.

Morgan Stanley has reiterated its Buy rating on Vir Biotechnology, setting a price target of $20.00. This optimistic outlook suggests substantial upside potential for the stock. Additionally, TD Cowen has maintained its Buy rating on VIR, further bolstering investor confidence in the biotechnology company.

These positive assessments from respected Wall Street analysts appear to be driving the stock's impressive performance today. Investors are likely interpreting these Buy ratings as indicators of Vir Biotechnology's strong market position and growth prospects in the competitive biotech sector.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10